Optiscan Imaging Limited

Equities

OIL

AU000000OIL4

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 11:27:00 17/05/2024 am IST			5-day change	1st Jan Change
0.11 ^AUD	-8.33%		+12.24%	+30.95%

13/05	Optiscan Imaging CEO to Host Mayo Clinic Agreement Webinar	MT
21/03	Optiscan Imaging Receives More Than AU$670,000 as R&D Tax Rebate	MT

Optiscan Imaging : APPOINTMENT OF NEW NON-EXECUTIVE CHAIR

April 19, 2021 at 09:40 am IST

We are delighted to announce the appointment of Mr Robert Cooke as the new non-executive Chair of the Board. Robert is the former Managing Director and CEO of Healthscope and has a highly successful track record as an executive leader of several publicly listed and private healthcare companies and the management of private and public hospitals in Australia, Asia and the UK. OptiScan welcomes the support Robert will bring to the current team at OptiScan in the next stage of its dynamic growth plans.

Full ASX announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02364628-3A565463?access_token=83ff96335c2d45a094df02a206a39ff4

Attachments

Original document
Permalink

Disclaimer

Optiscan Imaging Limited published this content on 19 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 April 2021 04:09:00 UTC.

Latest news about Optiscan Imaging Limited

Optiscan Imaging CEO to Host Mayo Clinic Agreement Webinar	13/05	MT
Optiscan Imaging Receives More Than AU$670,000 as R&D Tax Rebate	21/03	MT
Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02	CI
Optiscan Imaging Secures AU$3 Million Research Grant for Endomicroscope Device; Shares Rise 8%	13/02	MT
Optiscan Imaging Appoints COO	23/23/23	MT
Optiscan Imaging Limited Appoints Brendan Fafiani to the Role of Chief Operating Officer, Effective 6 November 2023	23/23/23	CI
Cancer Images from Optiscan's Platform Comparable With Conventional Histology Analysis, Study Says	20/23/20	MT
Optiscan Imaging Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
Optiscan Imaging Completes Key Milestone for Telepathology Project	15/23/15	MT
Optiscan Imaging Establishes New Commercial Operation in the US	03/23/03	MT
Optiscan Imaging Confirms High Diagnostic Rate of Imaging Device	14/23/14	MT
Optiscan Imaging Receives US FDA Feedback for Oral Imaging Product	02/23/02	MT
Optiscan Imaging Limited Intends to Pursue De Novo Pathway for InVivage	02/23/02	CI
Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2022	27/23/27	CI
Optiscan Imaging Limited Announces Partnership with Prolucid Technologies to Develop AI Algorithms	30/23/30	CI
Optiscan Imaging Proposes Issuance of 6 Million Securities	25/22/25	MT
Optiscan Imaging Acquiring Clinical Datasets from Managing Director; Shares Rise 4%	25/22/25	MT
Optiscan Imaging Secures R&D Tax Rebate	24/22/24	MT
Optiscan Imaging Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/22/31	CI
Optiscan Imaging Files US FDA Application for Oral Tissue Imaging Device	22/22/22	MT
Optiscan Submits FDA 510(k) Application for InVivage Device	22/22/22	CI
Optiscan Imaging Limited Announces Strategic Distribution Partnership - Additional Information	28/22/28	CI
Optiscan Imaging Appoints China Distributor for Research, Preclinical Device	27/22/27	MT
Optiscan Imaging Limited Announces Strategic Distribution Partner for China	27/22/27	CI
Optiscan Imaging Limited Appointment of Sean Gardiner as Non-Executive Director	14/22/14	CI

Chart Optiscan Imaging Limited

Duration

Period

More charts

Company Profile

Optiscan Imaging Limited is an Australia-based company, which is engaged in the development, manufacturing and commercialization of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The Companyâs technology enables real-time, non-destructive, three-dimensional (3D), in-vivo imaging at the single-cell level. It provides real-time microscopic imaging tools to healthcare providers and researchers to enable the early detection and management of disease. Its InVivage device is developed for clinical use in oral cancer and other cancer applications. Its Fluorescence In Vivo Endomicroscopy (FIVE2) also known as ViewnVivo system, is a hand-held, confocal microscope designed for pre-clinical use. This device is targeted for use by universities and medical research institutions to explore potential applications of the technology through laboratory testing of tissue samples.

Sector

Advanced Medical Equipment & Technology

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
OPTISCAN IMAGING LIMITED	+30.95%	61.42M
THERMO FISHER SCIENTIFIC	+12.15%	227B
DANAHER CORPORATION	+14.90%	197B
INTUITIVE SURGICAL, INC.	+18.22%	141B
BOSTON SCIENTIFIC CORPORATION	+29.15%	110B
SIEMENS HEALTHINEERS AG	+0.53%	64.15B
EDWARDS LIFESCIENCES CORPORATION	+16.92%	53.72B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.33%	51.75B
AGILENT TECHNOLOGIES, INC.	+10.93%	45.2B
GE HEALTHCARE TECHNOLOGIES INC.	+5.87%	37.37B

Other Advanced Medical Equipment & Technology